Publication Date:
2016-06-05
Description:
Article Targeted therapy of ErbB2-dependent tumours often provokes an adaptive response leading to reactivation of the PI3K/AKT pathway. Here the authors identify an ErbB3-independent compensatory mechanism comprising Ras/PI3K activation directly by ErbB2, and develop biparatopic panErbB inhibitors to block this mode of resistance. Nature Communications doi: 10.1038/ncomms11672 Authors: Rastislav Tamaskovic, Martin Schwill, Gabriela Nagy-Davidescu, Christian Jost, Dagmar C. Schaefer, Wouter P. R. Verdurmen, Jonas V. Schaefer, Annemarie Honegger, Andreas Plückthun
Electronic ISSN:
2041-1723
Topics:
Biology
,
Chemistry and Pharmacology
,
Natural Sciences in General
,
Physics
Permalink